Bimatoprost


Full Generic Medicine Info
Dosage/Direction for Use

Ophthalmic
Ocular hypertension
Adult: As 0.01% or 0.03% soln: Instill 1 drop into the affected eye(s) once daily at bedtime.

Ophthalmic
Open-angle glaucoma
Adult: As 0.01% or 0.03% soln: Instill 1 drop into the affected eye(s) once daily at bedtime.

Ophthalmic
Hypotrichosis of eyelashes
Adult: As 0.03% soln: Apply 1 drop evenly to each eye along the skin of the upper eyelid at the base of eyelashes once daily at bedtime.
Special Precautions
Patient w/ active intraocular inflammation (e.g. uveitis), aphakic patient, pseudophakic patient w/ torn posterior lens capsule, risk factor for macular oedema; history of herpes simplex, or uveitis/irits. Pregnancy and lactation. Patient Counselling Remove contact lenses prior to admin and reinsert after 15 min. May cause discolouration of soft contact lenses. Monitoring Parameters Monitor intraocular pressure.
Adverse Reactions
Ocular pruritus, swelling, irritation and burning sensation; conjunctival hyperaemia, dry eye symptoms, blurred vision, periorbital erythema, increased lacrimation, madarosis, trichorrhex, skin hyperpigmentation and discolouration, growth and darkening of eyelashes, hypersensitivity, rash (including macular, erythematous, and pruritic limited to eyelids and periorbital region); eyelid oedema, irritation and pruritus; periorbital and lid changes resulting in deepening of eyelid sulcus; headache, HTN, abnormal LFT.
Drug Interactions
May increase intraocular pressure w/ latanoprost. May reduce therapeutic effect w/ NSAIDs.
Action
Bimatoprost, a synthetic prostamide analogue, reduces intraocular pressure by increasing the outflow of aqueous humour. It also increases the percent and duration of hair in the growth phase.
Onset: Approx 4 hr.
Absorption: Absorbed through the cornea and sclera. Time to peak plasma concentration: W/in 10 min.
Distribution: Moderately distributed into body tissues. Volume of distribution: 0.67 L/kg. Plasma protein binding: Approx 88%.
Metabolism: Undergoes oxidation, N-deethylation and glucuronidation to form various metabolites.
Excretion: Via urine (up to 76%); faeces (25%). Elimination half-life: Approx 45 min.
Storage
Ophthalmic: Store between 2-25°C.
CIMS Class
Antiglaucoma Preparations / Other Eye Preparations
ATC Classification
S01EE03 - bimatoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Disclaimer: This information is independently developed by CIMS based on bimatoprost from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in